Type-2 Diabetes Clinical Trial
Official title:
The Effect of Supervised Exercise Programs on Exercise Capacity and Pulmonary Capacity in Type-2 Diabetic Patients
Verified date | April 2020 |
Source | Marmara University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Diabetes, beyond glycemic control, is a complex chronic disease that requires continuous
medical care with multifactorial risk reduction strategies. It is necessary to reduce the
likelihood of complications and additional problems that may develop in the long term. For
this reason, guiding the patient to manage the disease process, equipping and supporting the
patient with the necessary information is critical to prevent acute problems.
Exercise is the primary treatment method for diabetes patients. Exercise; It is the main
treatment method used to increase aerobic capacity and improve respiratory capacity due to
the positive effect it has on the body's structure and systems.
Status | Completed |
Enrollment | 28 |
Est. completion date | May 1, 2019 |
Est. primary completion date | March 15, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - patients with type-2 diabetes mellitus, - patients who have sedentary lifestyle (<3 bouts of exercise per week and <30 minutes aerobic exercise period), - non-smoking patients, - not to lose more than 5% of total body weight in the last 6 months, - blood pressure<160/100 mmHg Exclusion Criteria: - alcohol addiction in the last 12 months, - patients who use insulin hormone, - patients who have neuropathy or retinopathy, - patients who have an acute cardiac event in the last 6 weeks, - patients who have a disease at least 2 weeks in the last 1 month |
Country | Name | City | State |
---|---|---|---|
Turkey | Marmara University | Istanbul |
Lead Sponsor | Collaborator |
---|---|
Emresenocak |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incremental Shuttle Walk Test-ISWT | Aerobic Capacity | Baseline Assessment | |
Primary | Incremental Shuttle Walk Test-ISWT | Aerobic Capacity | End of the exercise period assessment (end of the 6. weeks) | |
Primary | Incremental Shuttle Walk Test-ISWT | Aerobic Capacity | End of the follow-up period assessment (end of the 12. weeks) | |
Primary | Digital Spirometer | FVC parameters were evaluated automatically. | Baseline Assessment | |
Primary | Digital Spirometer | FVC parameters were evaluated automatically. | End of the follow-up period assessment (end of the 6. weeks) | |
Primary | Digital Spirometer | FVC parameters were evaluated automatically. | End of the follow-up period assessment (end of the 12. weeks) | |
Primary | Digital Spirometer | FEV1 were evaluated automatically. | Baseline Assessment | |
Primary | Digital Spirometer | FEV1 were evaluated automatically. | End of the follow-up period assessment (end of the 6. weeks) | |
Primary | Digital Spirometer | FEV1 were evaluated automatically. | End of the follow-up period assessment (end of the 12. weeks) | |
Primary | Digital Spirometer | FEV1/FVC were evaluated automatically. | Baseline Assessment | |
Primary | Digital Spirometer | FEV1/FVC were evaluated automatically. | End of the follow-up period assessment (end of the 6. weeks) | |
Primary | Digital Spirometer | FEV1/FVC were evaluated automatically. | End of the follow-up period assessment (end of the 12. weeks) | |
Primary | Digital Spirometer | PEF parameters were evaluated automatically. | Baseline Assessment | |
Primary | Digital Spirometer | PEF parameters were evaluated automatically. | End of the follow-up period assessment (end of the 6. weeks) | |
Primary | Digital Spirometer | PEF parameters were evaluated automatically. | End of the follow-up period assessment (end of the 12. weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Completed |
NCT01264523 -
Nutritional Intervention With Moderately High-protein, Low-glycemic Load Products in Type-2 Diabetes Patients
|
N/A | |
Completed |
NCT04105608 -
GLP-1 and Oxyntomodulin Release in Relation to Diet in Type 2 Diabetes Patients.
|
N/A | |
Completed |
NCT03624803 -
DAPA - Egypt Study
|
||
Terminated |
NCT01787214 -
Walnuts and Glucose Variability
|
N/A | |
Completed |
NCT01715428 -
Liraglutide and Cardio-Metabolic Risk Markers
|
N/A | |
Completed |
NCT01884714 -
Exploring the Molecular Basis to Healthy Obesity: The Diabetes Risk Assessment Study
|
N/A | |
Completed |
NCT00567047 -
Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment
|
Phase 1 | |
Completed |
NCT02191644 -
Dietary Intervention Replacing Carbohydrate With Protein and Fat Has Greater Effect on Peripheral Blood Mononuclear Cell Metabolites Than on Plasma Metabolites in Patients With Prediabetes or Type-2 Diabetes
|
Phase 2 | |
Completed |
NCT01440660 -
Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER)
|
N/A | |
Completed |
NCT01343589 -
Effects of Milk Derived From Mountain-pasture Grazing Cows on Risk Markers of the Metabolic Syndrome Compared to Conventional Danish Milk
|
N/A | |
Completed |
NCT00651105 -
Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects
|
Phase 3 | |
Completed |
NCT03269058 -
Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04952948 -
Pilates Method on Functional Capacity and Blood Pressure of Elderly Women With Type 2 Diabetes
|
N/A | |
Completed |
NCT00478127 -
Hepatocyte Growth Factor and Cardiovascular Autonomic Function
|
N/A |